Drug cocktail may help radioactive iodine work better in tough thyroid cancers
NCT ID NCT06440850
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether two targeted drugs, vemurafenib and cobimetinib, can make thyroid cancer cells more responsive to radioactive iodine therapy. The study enrolls 21 adults with high-risk, BRAF-mutated thyroid cancer who have not yet received radioactive iodine. Participants take the drugs before their first radioactive iodine treatment to see if it improves cancer control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vemurafenib and cobimetinib
What this could lead to
If successful, this approach could make radioactive iodine therapy more effective for high-risk thyroid cancer patients with a BRAF mutation, potentially reducing cancer recurrence.
What could go wrong
This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The drugs can cause side effects like skin issues, fatigue, and liver problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND PAPILLARY CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact